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Abstract: The aim of this study was to test the effect of a plant-based dietary intervention on beta-cell
function in overweight adults with no history of diabetes. Participants (n = 75) were randomized to
follow a low-fat plant-based diet (n = 38) or to make no diet changes (n = 37) for 16 weeks. At baseline
and 16 weeks, beta-cell function was quantified with a mathematical model. Using a standard
meal test, insulin secretory rate was calculated by C-peptide deconvolution. The Homeostasis
Model Assessment (HOMA-IR) index was used to assess insulin resistance while fasting. A marked
increase in meal-stimulated insulin secretion was observed in the intervention group compared with
controls (interaction between group and time, Gxt, p < 0.001). HOMA-IR index fell significantly
(p < 0.001) in the intervention group (treatment effect −1.0 (95% CI, −1.2 to −0.8); Gxt, p = 0.004).
Changes in HOMA-IR correlated positively with changes in body mass index (BMI) and visceral fat
volume (r = 0.34; p = 0.009 and r = 0.42; p = 0.001, respectively). The latter remained significant after
adjustment for changes in BMI (r = 0.41; p = 0.002). Changes in glucose-induced insulin secretion
correlated negatively with BMI changes (r = −0.25; p = 0.04), but not with changes in visceral fat.
Beta-cell function and insulin sensitivity were significantly improved through a low-fat plant-based
diet in overweight adults.
Keywords: beta-cell function; diet; nutrition; diabetes; vegan
1. Introduction
Impairment of pancreatic beta-cell function, typically preceded by insulin resistance in muscle
and liver cells, is a key factor in type 2 diabetes [1]. Improvements in beta-cell function, however,
are not typically a goal of diabetes treatment. Beta-cell failure reflects a relative loss of beta-cell mass
due to apoptosis [2], as well as selective loss of sensitivity to glucose, along with the loss of first-phase
insulin secretion [3]. Limited data suggest that beta-cell function and beta-cell mass may be influenced
by diet [4–6] and physical activity [4].
Methods used for quantifying beta-cell function include the homeostasis model assessment
(HOMA), oral glucose tolerance tests, intravenous glucose tolerance tests, hyperglycemic clamp,
and standard meal tolerance tests. No single test allows beta-cell function to be assessed with
accuracy and specificity comparable to those of insulin sensitivity. Therefore, mathematical modeling
is necessary to interpret parameters of beta-cell function in all of the mentioned methods. The use of
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oral glucose tolerance tests or standard meal tests has been preferred due to simplicity but also for
physiological significance, as they include the gastrointestinal incretin effect that follows oral nutrient
ingestion [7,8].
Several prospective studies have demonstrated that diabetes prevalence is 46–74% lower among
individuals following plant-based diets, compared with the general (non-vegetarian) population,
even after adjustment for differences in BMI [5,6,9]. In addition, a vegan diet has been shown
to improve glycemic control in type 2 diabetes compared with a more conventional hypocaloric,
carbohydrate-controlled diet [10,11]. These studies raise the question as to whether such a diet
intervention could improve beta-cell function and insulin sensitivity. The aim of this study was to test
the effect of a dietary intervention on beta-cell function and insulin resistance in overweight adults
with no history of diabetes.
2. Materials and Methods
2.1. Study Design and Eligibility
The study was conducted between October 2016 and June 2017 in Washington, DC, using a
single-center, randomized, open parallel study. Men and women, aged 25 to 75 years, with a
body-mass index between 28 and 40 kg/m2, were enrolled. Exclusion criteria were history of
diabetes, smoking, alcohol or drug abuse, pregnancy or lactation, and current use of a vegan diet.
The study protocol was approved by the Chesapeake Institutional Review Board on 12 October 2016.
The protocol identification number is Pro00018983. All participants gave written informed consent.
Trial Registration: ClinicalTrials.gov number, NCT02939638.
2.2. Randomization and Study Groups
The participants were randomly assigned in a 1:1 ratio to an intervention group or a control group.
Participants were examined at baseline and at 16 weeks.
The intervention group was asked to follow a low-fat vegan diet (~75% of energy from
carbohydrates, 15% protein, and 10% fat) consisting of vegetables, grains, legumes, and fruits.
Participants were instructed to avoid animal products and added fats. Daily fat intake was 20–30 g
to ensure adequate intake of essential fatty acids. No meals were provided. Vitamin B12 was
supplemented (500 µg/day). The control group was asked to make no diet changes. Alcoholic
beverages were limited to one per day for women and two per day for men in both groups.
To monitor adherence, a 3-day dietary record was completed by each participant at baseline
and at 16 weeks. Dietary intake data were collected and analyzed by a registered dietician, using
Nutrition Data System for Research version 2016, developed by the Nutrition Coordinating Center
(NCC), University of Minnesota, Minneapolis, MN, USA [12]. In addition, study dietitians made
unannounced telephone calls to assess participants’ dietary adherence. All study participants were
asked not to alter their exercise habits, and to continue their preexisting medication regimens for the
duration of the study, except as modified by their personal physicians. Physical activity was assessed
by the International Physical Activity Questionnaire (IPAQ) [13].
2.3. Outcomes
All measurements were performed at baseline and 16 weeks on an outpatient basis, after a 10–12 h
overnight water-only fast. Height and weight were measured using a stadiometer and a periodically
calibrated scale accurate to 0.1 kg, respectively. Body composition was assessed using a DXA scan
(iDXA; GE Healthcare, Chicago, IL, USA).
Insulin secretion was assessed after stimulation with a liquid breakfast (Boost Plus, Nestle, Vevey,
Switzerland; 720 kcal, 34% of energy from fat, 16% protein, 50% carbohydrate). Plasma concentrations
of glucose, immunoreactive insulin, and C-peptide were measured at 0, 30, 60, 120, and 180 min.
Serum glucose was analyzed using the Hexokinase UV endopoint method (Roche, Basel, Switzerland).
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Plasma immunoreactive insulin and C-peptide concentrations were determined using insulin and
C-peptide electro-chemiluminescence immunoassay (ECLIA) kits (Roche, Basel, Switzerland). HbA1c
was measured by turbidimetric inhibition immunoassay (Roche, Basel, Switzerland). Plasma lipids
concentrations were measured by enzymatic colorimetric methods (Roche, Basel, Switzerland).
The primary outcome was beta-cell function assessed by a mathematical model [14–16], as follows:
Insulin secretory rates were calculated from plasma C-peptide concentrations by deconvolution [14]
and expressed per square meter of estimated body surface area. The dependence of insulin secretory
rates on glucose concentrations was modeled separately for each participant and each study day.
Insulin secretion consists of two components. The first represents the static dependence of insulin
secretion on glucose concentration and is characterized by a dose-response function. Its parameters
are insulin secretion at 5 mmol/L glucose (fasting glucose level) and mean slope in the glucose
range. The dose response is modulated by a potentiation factor, quantified as the ratio between
160–180 and 0–20 min values. The second component represents a dynamic dependence of insulin
secretion on the rate of change of glucose and is determined by the rate sensitivity [15,16]. The model
parameters (i.e., the parameters of the dose response, and the potentiation factor) were estimated from
glucose and C-peptide concentration by regularized least squares [14–16]. Regularization involves the
choice of smoothing factors that were selected to obtain glucose and C-peptide model residuals with
standard deviations close to the expected measurement error (~1% for glucose and ~5% for C-peptide).
C-peptide has been used for the calculation of insulin secretion, as it is secreted with insulin in an
equimolar fashion, but does not undergo liver elimination. Therefore, plasma C-peptide provides
a more accurate estimation of insulin secretion. Plasma insulin has been used for the assessment
of insulin sensitivity, both in fasting and stimulated conditions. Estimation of the individual model
parameters was performed by an investigator masked to group assignment.
The secondary outcome was insulin resistance calculated as Homeostasis Model Assessment
(HOMA-IR) index [17]. In addition, oral glucose insulin sensitivity index was calculated as a measure
of dynamic postprandial insulin sensitivity [18].
2.4. Statistical Analysis
The intention-to-treat analysis included all participants, regardless of their subsequent withdrawal
or non-adherence to the prescribed diet [19]. A repeated measure ANOVA model was used to test the
between-group differences from baseline to 16 weeks with between-subject and within-subject factors
and interactions. Group, subject and time were included in the model. Interaction between group and
time (Gxt) was calculated for each variable. For the dose-response analysis of insulin secretion as a
function of plasma glucose concentrations, glucose concentration was added to the ANOVA model.
Within each group, paired comparison t-tests were calculated to test whether the changes from baseline
to 16 weeks were statistically significant. Pearson correlations were calculated for the relationship
between changes in HOMA-IR and beta-cell function, and changes in BMI and volume of visceral fat.
3. Results
3.1. Characteristics of the Participants
Of 1082 people screened by telephone, 75 met the participation criteria and were randomly
assigned to the intervention (n = 38) or control (n = 37) groups, and 96% of participants completed
the study. Two participants dropped out of the control group and one from the intervention group,
all for reasons not related to the diet (Figure 1). Demographic characteristics are listed in Table 1.
Baseline physical activity, dietary intake, anthropometric and laboratory variables, parameters of
insulin resistance and beta-cell function, as well as their changes in response to the intervention are
shown in Table 2.
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Race, (number, %)   
White 15 (39%) 19 (51%) 
Black 20 (53%) 14 (38%) 
Asian, Pacific Islander 0 4 (11%) 
American Indian, Eskimo, Aleut 2 (5%) 0 
N/A—did not disclose 1 (3%) 0 
Ethnicity, (number, %)    
Non-hispanic 33 (87%) 31 (84%) 
Hispanic 3 (8%) 3 (8%) 
N/A—did not disclose 2 (5%) 3 (8%) 
Marital status   
Not married 22 (58%) 19 (51%) 
Married 16 (42%) 17 (46%) 
NA 0 1 (3%) 
Education   
High school 0 0 
College 17 (45%) 20 (54%) 
Graduate degree 20 (53%) 17 (46%) 
NA 1 (2%) 0 
Occupation   
Service occupation 5 (13%) 1 (3%) 
Technical, sales, administrative 15 (39%) 10 (27%) 
Professional or managerial 10 (26%) 16 (43%) 
Retired 4 (11%) 6 (16%) 
Other 4 (11%) 4 (11%) 
Medications   
Lipid-lowering therapy (%) 5 (13) 4 (11) 
Antihypertensive therapy (%) 11 (29) 7 (19) 
Thyroid medications (%) 6 (16) 3 (8) 
Figure 1. Enrollment of the participants and completion of the study.
Table 1. characteristics of the Study Population. Data are means ± SD, or number (%). p-values
refer to t-tests for continuous variable and χ2 for categorical variables. The p-value calculated for
ethnicity distribution is for he comparison between Hispanic vs. non-Hispanic ategories.
Characteristic Intervention Group (n = 38) Control Group (n = 37)
Age (years) 52.6 ± 14.7 54.3 ± 9.9
Sex (number, %)
Male 2 (5%) 6 (16%)
Female 36 (95%) 31 (84%)
Race, (number, %)
White 15 (39%) 19 (51%)
Black 20 (53%) 14 (38%)
Asian, Pacific Islander 0 4 (11%)
American Indian, Eskimo, Aleut 2 (5%) 0
N/A—did not disclose 1 (3%) 0
Ethnicity, (number, %)
Non-hispanic 33 (87%) 31 (84%)
Hispanic 3 (8%) 3 (8%)
N/A—did not disclose 2 (5%) 3 (8%)
Marital sta us
Not married 22 (58%) 19 (51%)
Married 16 (42%) 17 (46%)
NA 0 1 (3%)
Education
High scho l 0 0
College 17 (45%) 20 (54%)
Graduate degree 20 (53%) 17 (46%)
NA 1 (2%) 0
Occupation
Service occupation 5 (13%) 1 (3%)
Technical, sales, administrative 15 (39%) 10 (27%)
Professional or managerial 10 (26%) 16 (43%)
Retired 4 (11%) 6 (16%)
Other 4 (11%) 4 (11%)
Medications
Lipid-lowering therapy (%) 5 (13) 4 (11)
Antihypertensive therapy (%) 11 (29) 7 (19)
Thyroid medications (%) 6 (16) 3 (8)
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Table 2. Changes in dietary intake, clinical and laboratory variables during the study. Data are means ± SD. Listed p-values are for interactions between group and
time assessed by repeated measures ANOVA. * p < 0.05, ** p < 0.01 and *** p < 0.001 for within-group changes from baseline assessed by paired comparison t-tests.
Control Group Intervention Group
Treatment Effect p-Value
Baseline Week 16 Baseline Week 16
Total physical activity (METs) 2642 (1476–3809) 2575 (1169–3980) 2207 (1444–2969) 2490 (1586–3395) +351 (−1143 to +1846) 0.46
Dietary intake
Caloric intake (kcal/day) 1923 (1627–2219) 1582 (1368–1795) ** 1851 (1695–2007) 1450 (1249–1652) *** −60 (−352 to +233) 0.69
Carbohydrates (% of daily energy) 45.5 (42.6–48.4) 46.6 (42.9–50.4) 46.1 (43.5–48.8) 69.6 (67.3–71.8) *** +22.3 (+17.7 to +26.9) <0.001
Fats (% of daily energy) 35.6 (32.3–38.9) 35.0 (31.5–38.4) 36.1 (34.0–38.1) 17.5 (15.5–19.4) *** −17.9 (−22.3 to −13.6) <0.001
Proteins (% of daily energy) 16.1 (15.0–17.1) 17.0 (15.5–18.5) 16.8 (15.4–18.2) 12.3 (11.3–13.3) *** −5.4 (−7.8 to −3.0) <0.001
Fiber intake (g/day) 25.2 (20.9–29.6) 23.5 (19.6–27.4) 24.2 (21.0–27.4) 37.8 (31.4–44.1) *** +15.3 (+8.0 to +22.6) <0.001
Cholesterol intake (mg/day) 290 (220–360) 212 (149–275) 264 (213–315) 6.5 (2.5–10.5) *** −180 (−278 to −82) <0.001
Saturated fatty acids (g/day) 25.5 (19.8–31.1) 17.9 (13.6–22.2) ** 24.5 (21.2–27.7) 5.6 (4.6–6.7) *** −11.2 (−16.5 to −5.9) <0.001
Monounsaturated fatty acids (g/day) 30.5 (23.8–37.2) 24.9 (19.8–30.0) 28.9 (25.1–32.7) 9.5 (7.8–11.2) *** −13.8 (−19.5 to −8.2) <0.001
Polyunsaturated fatty acids (g/day) 20.9 (15.3–26.5) 17.9 (14.8–21.1) 18.2 (15.2–21.1) 10.6 (9.0–12.2) *** −4.6 (−10.1 to +0.9) 0.10
Glycemic index 58.1 (56.2–59.9) 57.4 (55.3–59.5) * 57.7 (55.5–59.9) 54.4 (53.4–55.5) ** −2.6 (−5.7 to +0.5) 0.10
Anthropometric variables
BMI (kg/m2) 33.6 (32.5–34.8) 33.4 (32.2–34.6) 33.1 (31.8–34.3) 31.2 (29.9–32.5) *** −2.0 (−2.6 to −1.5) <0.001
Lean mass (kg) 49.8 (46.2–53.4) 48.8 (45.4–52.2) ** 50.6 (48.6–52.5) 48.3 (46.5–50.1) *** −1.2 (−2.0 to −0.5) 0.002
Fat mass (kg) 39.1 (35.6–42.5) 39.5 (36.0–43.0) 42.0 (39.3–44.7) 38.1 (35.6–40.7) *** −4.3 (−5.4 to −3.2) <0.001
Visceral fat volume (cm3) 1434 (1154–1714) 1459 (1173–1744) 1289 (1040–1539) 1090 (864–1315) *** −224 (−328 to −120) <0.001
Laboratory variables
Total cholesterol (mmol/L) 5.4 (5.0–5.8) 5.3 (5.0–5.6) 5.4 (5.1–5.7) 4.8 (4.4–5.2) *** −1.1 (−2.0 to −0.2) 0.02
HDL-cholesterol (mmol/L) 1.6 (1.4–1.8) 1.6 (1.4–1.8) 1.6 (1.5–1.8) 1.4 (1.3–1.6) *** −0.4 (−0.6 to −0.2) 0.002
LDL-cholesterol (mmol/L) 3.2 (2.9–3.6) 3.2 (2.9–3.5) 3.2 (2.9–3.5) 2.7 (2.3–3.1) ** −0.9 (−1.8 to −0.1) 0.03
Triglycerides (mmol/L) 1.1 (0.9–1.4) 1.2 (0.9–1.6) 1.2 (1.0–1.3) 1.4 (1.2–1.7) ** +0.9 (−0.3 to +2.2) 0.16
Fasting plasma glucose (mmol/L) 5.5 (5.3–5.7) 5.6 (5.4–5.8) 5.3 (5.1–5.6) 5.1 (4.9–5.2) ** −0.4 (−0.6 to −0.2) <0.001
Fasting plasma insulin (pmol/L) 72.9 (56.9–88.2) 88.9 (38.9–135.4) 91.7 (72.9–111.8) 71.5 (55.6–87.5) ** −85.4 (−170.8 to +0.7) 0.05
Fasting plasma C-peptide (ng/mL) 2.5 (2.2–2.8) 3.0 (2.2–3.8) 2.6 (2.3–2.9) 2.1 (1.9–2.4) *** −1.0 (−1.6 to −0.4) 0.003
HbA1c (DCCT, %) 5.8 (5.7–5.9) 5.8 (5.7–5.9) 5.8 (5.7–5.9) 5.8 (5.7–5.9) 0.0 (−0.1 to +0.1) 0.81
HbA1c (IFCC, mmol/mol) 40 (38.8–41.2) 40.1 (38.8–41.4) 39.9 (38.3–41.4) 40.1 (38.9–41.4) +0.1 (−24.6 to +22.4) 0.81
Insulin secretion/ Beta-cell function
Basal insulin secretion (pmol/min/m2) 100.5 (94.4–107.2) 104.1 (97.7–111.3) 108.6 (102.2–115.8) 83.0 (78.9–87.5) ** −54.2 (−86.5 to −21.9) <0.001
Total insulin secretion (nmol/m2) 55.3 (52.6–58.2) 63.3 (60.4–66.4) ** 53.8 (51.4–56.3) 54.8 (52.4–57.3) −8.8 (−17.3 to +0.4) 0.07
Insulin secretion at a fixed glucose value (5 mM) (pmol/min/m2) 110.0 (99.6–121.1) 103.1 (93.9–112.8) 109.4 (100.1–119.4) 116.6 (105.9–128.1) * +14.2 (−25.0 to +63.3) 0.10
Mean glucose (mmol/L) 5.5 (5.2–5.8) 6.1 (5.7–6.4) *** 5.6 (5.2–6.0) 5.4 (4.9–5.9) * −0.8 (−1.2 to −0.4) <0.001
Mean insulin (pmol/L) 312.2 (234.4–390.0) 406.4 (316.8–496.0) * 330.0 (259.4–400.6) 348.6 (274.7–422.5) −75.7 (−180.4 to +29.1) 0.15
Glucose sensitivity (pmol/min/m2/mM) 107.5 (76.4–146.5) 181.1 (135.3–237.2) 108.5 (80.8–142.4) 213.8 (167.9–268.3) ** +65.5 (−74.4 to +205.4) 0.13
Rate sensitivity (pmol/m2/mM) 2260 (1419–3101) 1978 (1188–2768) 2783 (2127–3438) 2269 (1505–3033) −232 (−1601 to +1137) 0.38
Potentiation factor ratio (dimensionless) 1.45 (1.28–1.63) 1.62 (1.43–1.82) 1.32 (1.17–1.47) 1.08 (0.95–1.22) −0.51 (−1.04 to +0.03) 0.08
Insulin sensitivity /resistance
3 h-oral glucose insulin sensitivity (mL/min/m2) 403.2 (389.1–417.6) 388.2 (374.5–402.3) 404.1 (391.7–416.8) 406.7 (394.2–419.5) +10.8 (−29.5 to +51.1) 0.78
HOMA-IR (dimensionless) 2.4 (2.1–2.7) 2.8 (2.5–3.1) 2.5 (2.3–2.8) 1.9 (1.7–2.1) *** −1.0 (−1.2 to −0.8) 0.004
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3.2. Physical Activity and Dietary Intake
Physical activity did not change substantially in either group. Both groups reduced reported
energy intake (p < 0.001 for the intervention group, and p = 0.009 for controls), with no significant
difference between groups (p-value for interaction between the factors group and time, Gxt, p = 0.69).
Mean intake of carbohydrate, fat and protein did not change significantly in control participants, but
there were significant reductions in their mean saturated fatty acid intake (p = 0.002) and the glycemic
index of their diets (p = 0.03). The intervention group participants increased their mean intake of
carbohydrate (p < 0.001) and fiber (p < 0.001), while decreasing consumption of total fat (p < 0.001), as
well as saturated (p < 0.001), polyunsaturated (p < 0.001), and monounsaturated fatty acids (p < 0.001),
cholesterol (p < 0.001), and protein (p < 0.001).
3.3. Body Mass Index and Body Composition
Body mass index decreased significantly only in the intervention group (Gxt, p < 0.001). While lean
mass was reduced in both groups (Gxt, p = 0.002), fat mass, and particularly visceral fat volume,
were reduced only in the intervention group (Gxt, p < 0.001; Gxt, p < 0.001, respectively).
3.4. Laboratory Variables
Significant reductions in total (p < 0.001; Gxt, p = 0.02), LDL- (p = 0.002; Gxt, p = 0.03),
and HDL-cholesterol (p < 0.001; Gxt, p = 0.002), were observed in the intervention group. In addition,
fasting plasma glucose (p = 0.002; Gxt, p < 0.001), insulin (p = 0.01; Gxt, p = 0.05), and C-peptide
(p < 0.001; Gxt, p = 0.003) all fell in the intervention group. There were no significant changes in plasma
lipid concentrations or markers of glycemic control in the control group.
3.5. Beta-Cell Function
In the intervention group, we observed a decrease in basal insulin secretion (p = 0.006; treatment
effect −54.2 (95% CI −86.5 to −21.9) pmol/min/m2; Gxt, p < 0.001). The intervention group also
had increased beta-cell glucose sensitivity (p = 0.01), although the difference between groups did not
reach statistical significance (treatment effect +65.5 (95% CI −74.4 to +205.4) pmol/min/m2/mM;
Gxt, p = 0.13). Parameters of beta-cell function did not change significantly in controls, except for an
increase in total insulin secretion (p = 0.008). A marked dose-response increase in insulin secretion as a
function of plasma glucose concentrations (Figure 2) was observed in the intervention group compared
with controls (Gxt, p < 0.001).
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Figure 2. Dose-response insulin secretion in response to different plasma glucose levels. Triangles
with the blue line represent the control group (empty triangles and a dashed line at baseline, and full
triangles with a full line at 16 weeks), while squares with the red line show data from the intervention
group (empty squares with a dashed line at baseline, and full squares with a full line at 16 weeks).
Data are given as means with 95% CIs.
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3.6. Insulin Resistance
HOMA-IR index fell significantly (p < 0.001) in the intervention group, but did not change
significantly in controls (treatment effect −1.0 (95% CI, −1.2 to −0.8); Gxt, p = 0.004). No significant
change in oral glucose insulin sensitivity was observed in either group.
3.7. The Effect of BMI and Adiposity
Changes in HOMA-IR correlated positively with changes in BMI and volume of visceral fat
(r = 0.34; p = 0.009; and r = 0.42; p = 0.001); the latter remained significant even after adjustment for
changes in BMI (r = 0.41; p = 0.002). Changes in beta-cell function, evidenced by glucose-induced
insulin secretion, correlated negatively with changes in BMI (r = −0.25; p = 0.04), but not with changes
in visceral fat.
4. Discussion
In this randomized, controlled 16-week trial, beta-cell function and insulin resistance were altered
by a dietary intervention. The dietary intervention elicited marked increases in meal-stimulated
insulin secretion and beta-cell glucose sensitivity, along with decreased fasting insulin resistance and
decreased fasting and postprandial plasma glucose concentrations, in individuals with no history
of diabetes.
Previously, we [20] and others [4] demonstrated improvements in beta-cell function in individuals
with type 2 diabetes with an energy-restricted diet. The current study demonstrates that, in individuals
who are overweight but have no history of diabetes, a qualitative change in macronutrient
composition with no limit on energy intake, elicits an improvement in beta-cell function and fasting
insulin resistance.
In the control group, plasma glucose levels increased during the meal test, resulting in an
increase in total insulin secretion. Therefore, beta-cell glucose sensitivity (which is essentially secretion
“normalized” for plasma glucose levels) did not improve. This physiologic reaction of beta-cells to
compensate for impaired glycemic control, together with insulin resistance, which had a tendency
to increase in controls, are two main pathophysiologic mechanisms in development of beta-cell
dysfunction, and eventually diabetes [1], with reduced beta-cell function playing the decisive role [3].
Conversely, the intervention group participants improved their metabolic condition; glucose sensitivity
improved, as did fasting insulin sensitivity, with a decrease in fasting plasma glucose and mean glucose
levels during the meal test.
Fasting insulin resistance, calculated as the HOMA-IR index, decreased (i.e., improved) in the
intervention group, whereas no changes under dynamic postprandial conditions were observed in
either group. As fasting insulin resistance (HOMA-IR) primarily reflects hepatic insulin resistance
(whereas dynamic postprandial insulin sensitivity indices, such as oral glucose insulin sensitivity,
capture mainly skeletal muscle metabolism [18], our results suggest a marked improvement in hepatic,
rather than peripheral, insulin sensitivity. The decrease in insulin resistance was related to loss of
visceral fat, independent of changes in BMI, while changes in glucose-induced insulin secretion were
related to changes in BMI only. Our results are in accordance with a recent paper showing that
metabolic crosstalk of fatty liver with pancreatic islets may contribute to obesity-related impairment of
beta-cell glucose-sensitivity [21]. In this context, it seems plausible that a low-fat vegan diet in our study
decreased hepatic insulin resistance and led to a subsequent improvement in beta-cell function. This is
in line with the findings from the Finnish Diabetes Prevention Study, showing that the reduction in the
risk of development of type 2 diabetes after a lifestyle intervention is related to improvement in insulin
sensitivity, which has beneficial effects on preservation of beta-cell function [22,23]. However, we note
that our study assessed the effect of the intervention overall and was not designed to differentiate the
effects of the elimination of animal products, the reduction in overall fat intake, and the reduction
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in body weight that these changes elicit. Among lifestyle interventions associated with weight loss,
plant-based diets are particularly effective [24–26].
The improvement in plasma lipid concentrations in response to a low-fat vegan diet is in
accordance with previous studies, summarized in a recent meta-analysis, which showed that
plant-based diets are associated with decreased total cholesterol, both LDL-, and HDL-cholesterol,
but not with decreased triglycerides [27]. Improved blood lipids appear to play an important role in
the cardio-metabolic benefits and reduced all-cause mortality observed with vegetarian and vegan
diets [28].
Beta-cell function is improved by therapies that reduce body fat (such as diet and exercise,
GLP-1 agonists, or bariatric surgery) or change fat distribution (such as thiazolidinediones) [29,30].
Vegetarian and vegan diets have been shown to be effective for weight loss and particularly for
reduction in visceral fat and subfascial fat in muscle tissue [24,25,31,32], which is involved in glucose
homeostasis [33].
Additional possible mechanisms for improved beta-cell function observed with the dietary
intervention involve the incretin hormones, which are released from the gastrointestinal tract in
response to nutrient ingestion to enhance meal-dependent insulin secretion from the pancreas [34].
Compromised incretin action plays a role in the development of beta-cell dysfunction and type 2
diabetes [35]. We showed previously that a plant-based diet improved incretin secretion [36].
Therefore, in the present study, it is conceivable that the intervention diet may have improved beta-cell
function through enhanced incretin action. Other factors that have been hypothesized to be involved
in improvement of beta-cell function include reduced lipotoxicity, glucotoxicity, oxidative stress,
and inflammation; in theory, each of these can be influenced by diet [31,37]. A high-carbohydrate diet
has been shown to improve insulin sensitivity and meal-stimulated insulin secretion in individuals
with impaired fasting glucose [38]. Therefore, the substantially increased carbohydrate intake might
have played an important role in the improvement of beta-cell function in our study. In addition, while
dietary cholesterol has been shown to induce cellular and mitochondrial oxidative stress and lipid
peroxidation, leading to beta-cell dysfunction, quercetin and other polyphenols have anti-apoptotic,
antioxidant and anti-inflammatory properties and seem to improve ATP-linked mitochondrial energy
metabolism, thereby preserving meal-stimulated insulin secretion and beta-cell function [39,40].
The strengths of the study include the randomized parallel design, in which all participants
started simultaneously, allowing the investigators to rule out possible effects of seasonal fluctuations in
the diet. The study duration was reasonably long, providing sufficient time for adaptation to the diet.
We used physiological stimulation by a standard mixed meal, enabling us to study beta-cell function
during a physiological perturbation. A unique feature of our study lies in the detailed assessment of
beta-cell function, using mathematical modelling. The low attrition rate suggests that the intervention
was acceptable and sustainable, in accordance with the findings of a previous long-term study [11].
Given that the participants were living at home and preparing their own meals or eating at restaurants,
our results are applicable outside the research setting, in free-living conditions. The study also has
important limitations. Dietary intake was calculated based on self-reported diet records, which have
well-known limitations [41]. However, it is reassuring that the reported changes in nutrient intake were
paralleled by weight loss and metabolic changes. Our participants were generally health-conscious
individuals who were willing to make substantial changes to their diet. In this regard, they may not be
representative of the general population, but may be representative of a clinical population seeking
help for weight problems.
5. Conclusions
In conclusion, we have demonstrated that beta-cell function and fasting insulin sensitivity can be
modified by a 16-week dietary intervention. Our study suggests the potential of a low-fat plant-based
diet in diabetes prevention, addressing both core pathophysiologic mechanisms—insulin resistance
and diminished beta-cell function—at the same time.
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